31.66
+0.94(+3.06%)
Currency In USD
| Previous Close | 30.72 |
| Open | 30.96 |
| Day High | 32.07 |
| Day Low | 30.52 |
| 52-Week High | 35.55 |
| 52-Week Low | 4.81 |
| Volume | 418,804 |
| Average Volume | 821,408 |
| Market Cap | 1.06B |
| PE | 4.13 |
| EPS | 7.67 |
| Moving Average 50 Days | 28.49 |
| Moving Average 200 Days | 16.27 |
| Change | 0.94 |
If you invested $1000 in MBX Biosciences, Inc. Common Stock (MBX) since IPO date, it would be worth $1,338.69 as of January 11, 2026 at a share price of $31.66. Whereas If you bought $1000 worth of MBX Biosciences, Inc. Common Stock (MBX) shares 1 year ago, it would be worth $1,338.69 as of January 11, 2026 at a share price of $31.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
5 hours ago
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
GlobeNewswire Inc.
Dec 15, 2025 1:00 PM GMT
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabol
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Nov 18, 2025 1:00 PM GMT
CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabol